Table 2:
Unadjusted and adjusted analyses of cancer risk comparing patients with type 2 diabetes who are metformin users or non-users with those without diabetes, within the DM1 and DM1-free cohorts
| Analysis | DM1 Cohort | DM1-free Cohort | ||||
|---|---|---|---|---|---|---|
| (n=913) | (n=12,318) | |||||
| HR | (95% CI) | p-value | HR | (95% CI) | p-value | |
| Unadjusted | ||||||
| No Diabetes | Reference | Reference | ||||
| T2D (metformin non-users) | 3.74 | (1.28 to 10.91) | 0.02 | 1.36 | (0.87 to 2.12) | 0.18 |
| T2D (metformin users) | 0.58 | (0.08 to 4.25) | 0.59 | 1.54 | (1.11 to 2.12) | 0.01 |
| Adjusted* | ||||||
| No Diabetes | Reference | Reference | ||||
| T2D (metformin non-users) | 3.60 | (1.18 to 10.97) | 0.02 | 1.13 | (0.72 to 1.79) | 0.59 |
| T2D (metformin users) | 0.43 | (0.06 to 3.35) | 0.42 | 1.28 | (0.91 to 1.79) | 0.16 |
*
Adjusted for sex, baseline BMI (continuous), linkage status (time-dependent starting April 1997), and number of healthcare encounters (in CPRD and/or HES prior to outcome/end of follow-up date, with a 1-year time lag)